{"id":2525,"date":"2016-12-15T00:00:00","date_gmt":"2016-12-14T23:00:00","guid":{"rendered":"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/"},"modified":"2019-01-13T16:39:30","modified_gmt":"2019-01-13T15:39:30","slug":"15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2","status":"publish","type":"post","link":"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/","title":{"rendered":"NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda\u00ae (Pembrolizumab) in panacreatic and colorectal Cancer (2)"},"content":{"rendered":"<p><strong><br \/><\/strong><\/p>\n<p><span><strong>Berlin, Germany, 15 December 2016<\/strong>&nbsp;&#8211; NOXXON Pharma N.V. (Alternext: ALNOX) today announces the signature of a collaboration agreement with Merck &amp; Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada), under which the two companies will collaborate in a phase 1\/2 clinical trial of NOXXON\u2019s anti-CXCL12 agent, NOX-A12, and MSD\u2019s anti-PD-1 inhibitor, Keytruda\u00ae (pembrolizumab), in patients with metastatic solid tumors that do not usually respond to checkpoint inhibitor monotherapy.<\/span><\/p>\n<p><span><br \/><\/span><\/p>\n<p>The goal of the two-part, open-label phase 1\/2 study is to evaluate pharmacodynamic effects and safety of NOX-A12 as a monotherapy in addition to safety and efficacy of NOX-A12 in combination with Keytruda\u00ae in patients with metastatic colorectal and pancreatic cancer. A total of twenty patients will be recruited, ten of each cancer type. NOXXON will be the sponsor of the study, which will be conducted in Europe.<\/p>\n<p>The design of the clinical trial was a collaborative effort between NOXXON and MSD. Part 1 of the study, in which patients will receive NOX-A12 monotherapy for up to two weeks, will evaluate immune infiltrate changes within the tumor microenvironment induced by CXCL12 inhibition with NOX-A12 by comparing pre- and post-treatment biopsy specimens as well as the safety and tolerability of NOX-A12 in patients with metastatic (stage IV) colorectal and pancreatic cancer. Part 2 of the study, in which NOX-A12 is to be combined with Keytruda\u00ae, will assess the safety and tolerability of the combination in addition to the efficacy of treatment.<\/p>\n<p>NOX-A12, which inhibits the key tumor microenvironment chemokine CXCL12, may be a key partner for a wide range of IO (immuno-oncology) agents. NOXXON has generated promising pre-clinical and clinical data, including recent animal data showing synergy with a checkpoint inhibitor, as well as recent phase 2a trials in multiple myeloma and a second hematological cancer that showed a safety profile that supports further development and first signs of efficacy. NOXXON believes that its planned clinical study will position the drug to be combined with multiple classes of IO approaches including those acting on or through T cells and\/or NK cells.<\/p>\n<p>Under the collaboration agreement, MSD will provide Keytruda\u00ae to NOXXON for the conduct of the trial and has approved the trial design. Multiple paths for further development of the combination in pivotal clinical trials are envisioned in this agreement, although the agreement grants no commercial rights to either party for the other party\u2019s compound. Additional details were not disclosed.<\/p>\n<p>Aram Mangasarian, PhD, Chief Executive Officer of NOXXON commented: \u201cThis collaboration with MSD allows us to initiate a clinical trial of NOX-A12 in patients with metastatic solid tumors with the advice and support of one of the key players in the immuno-oncology space. We are pleased that MSD shares our interest in the potential of the CXCL12 pathway to modulate the tumor microenvironment to increase the efficacy of checkpoint therapy.\u201d<\/p>\n<p>KEYTRUDA\u00ae is a registered trademark of Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Kenilworth, NJ, USA.<\/p>\n<!--themify_builder_content-->\n<div id=\"themify_builder_content-2525\" data-postid=\"2525\" class=\"themify_builder_content themify_builder_content-2525 themify_builder tf_clear\">\n    <\/div>\n<!--\/themify_builder_content-->\n","protected":false},"excerpt":{"rendered":"<p>NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda\u00ae (Pembrolizumab) in panacreatic and colorectal Cancer (2) - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda\u00ae (Pembrolizumab) in panacreatic and colorectal Cancer (2) - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"og:description\" content=\"NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"article:published_time\" content=\"2016-12-14T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-01-13T15:39:30+00:00\" \/>\n<meta name=\"author\" content=\"norman.krey\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"norman.krey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/\"},\"author\":{\"name\":\"norman.krey\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b\"},\"headline\":\"NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda\u00ae (Pembrolizumab) in panacreatic and colorectal Cancer (2)\",\"datePublished\":\"2016-12-14T23:00:00+00:00\",\"dateModified\":\"2019-01-13T15:39:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/\"},\"wordCount\":515,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"articleSection\":[\"Portfolio News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/\",\"url\":\"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/\",\"name\":\"NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda\u00ae (Pembrolizumab) in panacreatic and colorectal Cancer (2) - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/#website\"},\"datePublished\":\"2016-12-14T23:00:00+00:00\",\"dateModified\":\"2019-01-13T15:39:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/dewb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda\u00ae (Pembrolizumab) in panacreatic and colorectal Cancer (2)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dewb.de\/en\/#website\",\"url\":\"https:\/\/dewb.de\/en\/\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"description\":\"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website\",\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dewb.de\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dewb.de\/en\/#organization\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"url\":\"https:\/\/dewb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"contentUrl\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"width\":300,\"height\":82,\"caption\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\"},\"image\":{\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b\",\"name\":\"norman.krey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g\",\"caption\":\"norman.krey\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda\u00ae (Pembrolizumab) in panacreatic and colorectal Cancer (2) - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/","og_locale":"en_US","og_type":"article","og_title":"NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda\u00ae (Pembrolizumab) in panacreatic and colorectal Cancer (2) - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","og_description":"NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion","og_url":"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/","og_site_name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","article_published_time":"2016-12-14T23:00:00+00:00","article_modified_time":"2019-01-13T15:39:30+00:00","author":"norman.krey","twitter_card":"summary_large_image","twitter_misc":{"Written by":"norman.krey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/#article","isPartOf":{"@id":"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/"},"author":{"name":"norman.krey","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b"},"headline":"NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda\u00ae (Pembrolizumab) in panacreatic and colorectal Cancer (2)","datePublished":"2016-12-14T23:00:00+00:00","dateModified":"2019-01-13T15:39:30+00:00","mainEntityOfPage":{"@id":"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/"},"wordCount":515,"commentCount":0,"publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"articleSection":["Portfolio News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/","url":"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/","name":"NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda\u00ae (Pembrolizumab) in panacreatic and colorectal Cancer (2) - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","isPartOf":{"@id":"https:\/\/dewb.de\/en\/#website"},"datePublished":"2016-12-14T23:00:00+00:00","dateModified":"2019-01-13T15:39:30+00:00","breadcrumb":{"@id":"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dewb.de\/en\/15-12-16-noxxon-pharma-signs-clinical-immuno-oncology-collaboration-agreement-with-msd-to-study-nox-a12-combined-with-keytruda-pembrolizumab-in-panacreatic-and-colorectal-cancer-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/dewb.de\/en\/"},{"@type":"ListItem","position":2,"name":"NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda\u00ae (Pembrolizumab) in panacreatic and colorectal Cancer (2)"}]},{"@type":"WebSite","@id":"https:\/\/dewb.de\/en\/#website","url":"https:\/\/dewb.de\/en\/","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","description":"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website","publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dewb.de\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dewb.de\/en\/#organization","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","url":"https:\/\/dewb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","contentUrl":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","width":300,"height":82,"caption":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG"},"image":{"@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b","name":"norman.krey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g","caption":"norman.krey"}}]}},"builder_content":"","_links":{"self":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2525"}],"collection":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/comments?post=2525"}],"version-history":[{"count":1,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2525\/revisions"}],"predecessor-version":[{"id":2652,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2525\/revisions\/2652"}],"wp:attachment":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/media?parent=2525"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/categories?post=2525"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/tags?post=2525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}